CBD Offers Patients a New Route for Dealing With Chronic Symptoms

NEW YORK, May 14, 2020 /PRNewswire/ -- While cannabis legalization is rapidly spreading, the plant is still considered a Schedule 1 controlled substance under federal regulations. And despite medical breakthroughs, there is still concern over the broad use of cannabis. Regulators are worried about the potential abuse of marijuana, which is a plant within the cannabis family. There is greater concern with the marijuana counterpart mainly because of its main active ingredient: THC or tetrahydrocannabinol, which is typically known to cause psychoactive effects on its consumers. However, with ongoing clinical trials and research, health officials have begun to realize that cannabis can be used as a potential medical treatment. Following the emergence of the legal cannabis market, the number of users steadily began to rise. Principally, most consumers are medical patients using cannabis to ease symptoms related with cancer, HIV/AIDS, multiple sclerosis, epilepsy, Alzheimer's, Parkinson's, and chronic pain. As a result, the global marijuana market is expected to grow from USD 42.20 Billion in 2017 to USD 466.81 Billion by 2025 while registering a CAGR of 35.3%, according to data compiled by Verified Market Intelligence. World High Life Plc (OTC: WRHLF) (AQSE: LIFE), Cronos Group Inc. (NASDAQ: CRON), Aleafia Health Inc. (OTC: ALEAF) (TSX: ALEF), Trulieve Cannabis Corporation (OTC: TCNNF), Planet 13 Holdings Inc. (OTC: PLNHF

Overall, there are hundreds of studies being conducted to evaluate the efficacy of CBD. Notably, researchers are advancing studies to further promote the use of CBD for Parkinson's treatment. Currently, the research on CBD for Parkinson's is very limited and most studies are likely small-scale trials. However, the handful of studies that have been conducted suggest that CBD can have positive effects when dealing with nonmotor symptoms. For example, Rachel Dolhun, MD, Vice President, Medical Communications at The Michael J. Fox Foundation for Parkinson's Research explained that "the work to date on marijuana and cannabinoids has given promising but conflicting signals on potential benefit for motor and non-motor symptoms as well as levodopa-induced dyskinesia. This therapy may represent a future treatment option for PD, but the correct dose and formulation are not clear, full side effects and drug interactions are unknown, and benefits have not been rigorously determined. Future studies should be large and well designed to provide clear data on the safety and efficacy of marijuana and cannabinoids in Parkinson's."

World High Life Plc (OTCQB: WRHLF) (AQSE: LIFE) just announced breaking news that it,"congratulates Georges St-Pierre on the announcement of his induction into the UFC Hall of Fame.

Georges St-Pierre serves as brand ambassador for World High Life and its wholly owned subsidiary Love Hemp Ltd. Mr. St-Pierre has been inducted into the UFC Hall of Fame as a member of the Class of 2020.

'Georges St-Pierre is a globally recognized icon, his success in mixed martial arts is legendary for two reasons, his winning record and his incredible commitment to preparation,' said Mr. David Stadnyk, World High Life Founder and CEO. 'We congratulate him for this honour he has earned - having his championship pedigree and commitment to excellence on our team is inspiring as we continue to grow the business with him, aimed at achieving the highest standards.'

3-time UFC World Champion (2 time Welterweight and 1-time Middleweight), Georges St-Pierre holds a record of 26-2-0 in his professional fight career, avenging both losses. He will enter the UFC Hall of Fame's "Modern Wing," honouring fighters who debuted in the era of unified rules post November 2000, and who are at least 35 and have been retired for a minimum of one year."

For our latest "Buzz on the Street" Show featuring World High Life Plc. recent corporate news, please head over to: https://www.youtube.com/watch?v=Lpx4eZxmR2s

Cronos Group Inc. (NASDAQ: CRON) announced last September that it had closed itspreviously announced acquisition of four Redwood Holding Group, LLC operating subsidiaries. The transaction provides Cronos Group with a leading U.S. hemp-based products platform, including hemp-derived cannabidiol infused skincare and other consumer products that are sold online and through retail and hospitality partner channels in the United States under the brand, Lord Jones™.  Mike Gorenstein, Cronos Group's Chairman, President and Chief Executive Officer, said, "this acquisition is one of a number of new growth opportunities that is differentiating our company and our strategic direction. We are pleased to have completed this acquisition and look forward to working closely with Rob and Cindy to further build on their record of innovation and fully capitalize on the platform they have created.

Aleafia Health Inc. (OTCQX: ALEAF) (TSX: ALEF) wholly owned subsidiary Emblem Cannabis Corp. announced last week that it had secured a Health Canada Licence Amendment for its Paris Facility's 30,000 sq. ft. Phase II expansion, entirely dedicated to the extraction, production, packaging and distribution of finished cannabis products. "The Phase II expansion, our crown jewel, permits an exponential increase in our ability to produce and sell high-margin cannabis health and wellness products in the medical, adult-use and international markets," said Aleafia Health CEO Geoffrey Benic. "The Paris Facility's state-of-the-art expansion, purpose built to meet EU-GMP standards, creates a unique competitive advantage with significant barriers to entry. Coupled with our ultra-low-cost outdoor cultivation, it sets us apart in the cannabis industry. This means greater breadth of formats, greater scale and automation, and ultimately higher margins as we utilize cannabis grown outdoors through our integrated production ecosystem."

Trulieve Cannabis Corporation (OTCQX: TCNNF) announced earlier in April the launch of a new product, Blue River™ Rosin Cart, through the successful partnership with Blue River™. Blue River™ Rosin is a strain-specific, full-spectrum, solvent-less hash oil. The Blue River™ Rosin Cart offers patients a safe, convenient, and controlled way to vaporize in a strain-specific solventless manner. Using advanced mechanical separation techniques, Blue River™ can naturally preserve a higher concentration of full-spectrum cannabinoids and terpenes without the use of water, chemical solvents, or other additives. "Trulieve is excited to extend our partnership with Blue River, adding to their award-winning terpene extracts, THCa and other trademark branded products on Trulieve's shelves for Florida's growing patient base," said Trulieve's Chief Marketing Officer, Valda Coryat.  "Blue River's Rosin Cart adds to our innovative focus, delivering more effective and enhanced experiences for our Truliever community."

Planet 13 Holdings Inc. (OTCQX: PLNHF) announced last month that following the announcement on April 13th, 2020 that it had terminated a definitive agreement to acquire a cannabis sales license and lease for a dispensary in Santa Ana, California from Newtonian Principles, Inc., it has renegotiated the terms of Acquisition and has entered into an amendment to the Initial Definitive Agreement. "We've evaluated hundreds of locations in California and continue to believe that our Santa Ana location is the best suited for a Planet 13 style dispensary," said Bob Groesbeck Co-CEO of Planet 13. "While we can't forecast how COVID-19 might affect our timeline, we've negotiated an agreement that reduces the upfront capital invested, gives us control over the timing of fixed costs and provides flexibility on dispensary buildout. We de-risked the transaction substantially while securing the next stage of growth for Planet 13."

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com 

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. FinancialBuzz.com has not been compensated directly by any of the companies mentioned here in this editorial unless mentioned otherwise. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For World High Life Plc financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.FinancialBuzz.com.

Media Contact:
info@financialbuzz.com
+1-877-601-1879
www.FinancialBuzz.com

 

Cision View original content:http://www.prnewswire.com/news-releases/cbd-offers-patients-a-new-route-for-dealing-with-chronic-symptoms-301059059.html

SOURCE FinancialBuzz.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.